BioAmber Inc fka BIOAQ

[bioaq_sh]

iF Mitsui's security agreement w/ Bioamber was null & void upon the vesting order and/or closing of the CCAA;

Why would LCY wait to request 2 seperate patent assignments (1st in April 2022, 2nd on January 25, 2023) from Mitsui?

IMO, it seems there was a (confidential) agreement between LCY & MITSUI which included achieving certain milestones such as Mitsui receiving $13-17 million USD worth of bio-succinic acid before certain patent assignments were conveyed.

As an example & considering upon signing the security agreement, Bioamber assigned those same patents and trademarks to Mitsui all within the same month of August 2017.

And to my original point, 1 day after the January 25, 2023 LCY patent assignment for Bioamber's bio-succinic production process, or 1-month after Mitsui received their last shipment of bio-succinic acid, Articles are published quoting LCY Biosciences' production shifting focus over to carotenoids.